Contract manufacturing powerhouse Lonza is set to enhance its capabilities in the production of antibody-drug conjugates (ADCs) through an expanded partnership with a significant U.S. drugmaker. This strategic move, announced this week, underscores Lonza’s commitment to addressing the growing demand for ADCs, which are increasingly pivotal in oncology therapeutics.
The expansion not only reflects Lonza’s proactive approach to scaling its manufacturing capabilities but also highlights the evolving landscape of pharmaceutical partnerships. By increasing the scope of its collaboration with a major player in the U.S. market, Lonza positions itself to better meet the needs of its clients while reinforcing its competitive edge in the biopharmaceutical sector.
This development may have broader implications for the industry, as it signals a trend towards more integrated and responsive supply chains in the production of complex biologics. As ADCs gain traction, the ability to efficiently scale production will be crucial for companies looking to innovate and bring new therapies to market.
Start your 7-day trial and see what the database can do →
